Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.

ABSTRACT: Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the objective of sharing these practice-based insights on the use of burosumab in children and adolescents with XLH. We attended two virtual meetings, then discussed key questions via Within3, a virtual online platform. Points of discussion related to patient selection criteria, burosumab starting dose, dose titration and treatment monitoring. Our discussions revealed that criteria for selecting children with XLH varied across Europe from all children above 1 year to only children with overt ricket

SUBMITTER: Mughal MZ 

PROVIDER: S-EPMC9928183 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature